SYRE — Spyre Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1636282 ·
Last close
$97.74
Market Cap
$8.49B
52W High
$102.06
52W Low
$59.02
ADV30
1,602,144
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -75,641,000 | -69,005,000 | 763,953,000 | 97,185,000 | 93,142,000 |
| Dec 2025 | 0 | — | -57,172,000 | -62,530,000 | 777,781,000 | 85,721,000 | 62,545,000 |
| Sep 2025 | 0 | — | -56,888,000 | -11,183,000 | 504,604,000 | 64,897,000 | 49,504,000 |
| Jun 2025 | 0 | — | -51,935,000 | -36,717,000 | 538,832,000 | 81,659,000 | 83,059,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-169,252,000
Investing CF
$-143,475,000
Financing CF
$309,025,000
CapEx
—
Dividends Paid
—
Buybacks
$-117,000
EPS Diluted TTM
$-2.09
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,127,635,000
Inventory
—
Receivables
—
ST Investments
$670,812,000
EBIT TTM
$-219,562,000
Pretax Income TTM
$-155,218,000
Interest Exp TTM
—
Analysts
15
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -219,562,000 | -155,203,000 | 777,781,000 | 62,545,000 | — | -169,252,000 |
| Dec 2024 | 0 | -208,566,000 | -208,018,000 | 608,484,000 | 90,680,000 | — | -157,410,000 |
| Dec 2023 | 886,000 | -128,564,000 | -338,790,000 | 341,859,000 | 157,843,000 | — | -99,910,000 |
| Dec 2022 | 2,329,000 | -84,781,000 | -83,815,000 | 71,144,000 | 20,839,000 | — | -80,144,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$174,000
NetIncome TTM
$-127,369,000
OpCashFlow TTM
$0
Assets (Latest)
$608,484,000
Forward EPS
$-3.13
Max Pain — expiry 2026-08-21
max pain strike: $85.00 · spot: $97.74 · call oi: 2,086 · put oi: 2,488Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc | $8.45B | $131.42 | — |
| ALKS | Alkermes plc. | $8.66B | $51.94 | — |
| TGTX | TG THERAPEUTICS, INC. | $8.74B | $57.12 | — |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.85B | $83.58 | — |
| PRAX | Praxis Precision Medicines, Inc. | $9.06B | $324.99 | — |
News headlines (Yahoo Finance, 1h cache)
Spyre Therapeutics Announces Grants of Inducement Awards
2026-07-02 20:05 · Yahoo
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts
2026-06-29 15:16 · Yahoo
Spyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE)
2026-06-24 12:53 · Yahoo
cAMPfield lands $180M to build gut disease drug
2026-06-18 11:45 · Yahoo
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
2026-06-15 12:00 · Yahoo
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up
2026-06-04 14:56 · Yahoo
Spyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside Potential
2026-06-04 09:07 · Yahoo
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
2026-06-03 12:00 · Yahoo
Why Spyre Therapeutics (SYRE) Is Down 6.1% After Broadening Its SPY003 Paragon License Terms
2026-06-02 22:07 · Yahoo
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
2026-05-17 19:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.